MICHAEL SEVERINO - 23 May 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
Vice Chairman
Signature
Steven L. Scrogham, attorney-in-fact for Michael Severino
Issuer symbol
ABBV
Transactions as of
23 May 2022
Net transactions value
-$12,041,780
Form type
4
Filing time
25 May 2022, 16:58:03 UTC
Previous filing
18 May 2022
Next filing
15 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $5,297,155 +46,320 +30% $114.36 198,423 23 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $1,097,877 +11,742 +5.9% $93.50 210,165 23 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Options Exercise $2,302,595 +21,739 +10% $105.92 231,904 23 May 2022 Direct
transaction ABBV Common Stock, $0.01 par value Sale $10,283,275 -68,196 -29% $150.79 163,708 23 May 2022 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $1,758,506 -11,605 -7.1% $151.53 152,103 23 May 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Options Exercise $5,297,155 -46,320 -100% $114.36 0 23 May 2022 Common Stock 46,320 $114.36 Direct F3
transaction ABBV Option (Right to Buy) Options Exercise $1,097,877 -11,742 -24% $93.50 38,188 23 May 2022 Common Stock 11,742 $93.50 Direct F3
transaction ABBV Option (Right to Buy) Options Exercise $2,302,595 -21,739 -33% $105.92 43,478 23 May 2022 Common Stock 21,739 $105.92 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.13 to $151.12 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.13 to $151.58 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).